Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States.
Share Price & News
How has Chemed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: CHE's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CHE underperformed the US Healthcare industry which returned 33% over the past year.
Return vs Market: CHE underperformed the US Market which returned 33.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Chemed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StShareholders Are Optimistic That Chemed (NYSE:CHE) Will Multiply In Value
1 month ago | Simply Wall StThis Insider Has Just Sold Shares In Chemed Corporation (NYSE:CHE)
1 month ago | Simply Wall StDeclining Stock and Solid Fundamentals: Is The Market Wrong About Chemed Corporation (NYSE:CHE)?
Chemed Fundamentals Summary
|CHE fundamental statistics|
Is CHE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CHE income statement (TTM)|
|Cost of Revenue||US$1.37b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||19.04|
|Net Profit Margin||14.30%|
How did CHE perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Is Chemed undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CHE ($475.52) is trading above our estimate of fair value ($211.24)
Significantly Below Fair Value: CHE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CHE is poor value based on its PE Ratio (24.7x) compared to the US Healthcare industry average (22.6x).
PE vs Market: CHE is poor value based on its PE Ratio (24.7x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: CHE is poor value based on its PEG Ratio (11.6x)
Price to Book Ratio
PB vs Industry: CHE is overvalued based on its PB Ratio (8.6x) compared to the US Healthcare industry average (3.4x).
How is Chemed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHE's forecast earnings growth (2.1% per year) is above the savings rate (2%).
Earnings vs Market: CHE's earnings (2.1% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: CHE's earnings are forecast to grow, but not significantly.
Revenue vs Market: CHE's revenue (3.8% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: CHE's revenue (3.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHE's Return on Equity is forecast to be high in 3 years time
How has Chemed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHE has high quality earnings.
Growing Profit Margin: CHE's current net profit margins (14.3%) are higher than last year (13%).
Past Earnings Growth Analysis
Earnings Trend: CHE's earnings have grown significantly by 26.2% per year over the past 5 years.
Accelerating Growth: CHE's earnings growth over the past year (15.6%) is below its 5-year average (26.2% per year).
Earnings vs Industry: CHE earnings growth over the past year (15.6%) underperformed the Healthcare industry 32.2%.
Return on Equity
High ROE: CHE's Return on Equity (34.8%) is considered high.
How is Chemed's financial position?
Financial Position Analysis
Short Term Liabilities: CHE's short term assets ($269.1M) exceed its short term liabilities ($267.4M).
Long Term Liabilities: CHE's short term assets ($269.1M) exceed its long term liabilities ($245.6M).
Debt to Equity History and Analysis
Debt Level: CHE is debt free.
Reducing Debt: CHE has no debt compared to 5 years ago when its debt to equity ratio was 31.8%.
Debt Coverage: CHE has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CHE has no debt, therefore coverage of interest payments is not a concern.
What is Chemed current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CHE's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: CHE's dividend (0.3%) is low compared to the top 25% of dividend payers in the US market (3.6%).
Stability and Growth of Payments
Stable Dividend: CHE is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: CHE is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CHE is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin McNamara (67 yo)
Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and has been its President since August 2, 1994. Previously, Mr. McNamara served as an Executive Vice Preside...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD11.96M) is above average for companies of similar size in the US market ($USD6.44M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Experienced Management: CHE's management team is seasoned and experienced (17.5 years average tenure).
Experienced Board: CHE's board of directors are seasoned and experienced ( 13.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CHE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Chemed Corporation's company bio, employee growth, exchange listings and data sources
- Name: Chemed Corporation
- Ticker: CHE
- Exchange: NYSE
- Founded: 1970
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$7.481b
- Shares outstanding: 15.73m
- Website: https://www.chemed.com
Number of Employees
- Chemed Corporation
- 255 East Fifth Street
- Suite 2600
- United States
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United Stat...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:04|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.